SMAD7 and inflammatory bowel disease: Smad7 inhibition in IBD patients with an oral Smad7 AS-containing pharmaceutical compound showed conflicting clinical results, and further studies are ongoing to possibly confirm the efficacy of such approach in clinical practice.